Edinburgh – 19th May 2008: Lab901 Ltd. today announced that it has signed a distribution deal with the Korean PCR diagnostics firm Seegene Inc.
Under the deal, Lab901 has appointed Seegene as its exclusive diagnostics distributor for the ScreenTape® system in the Korean market. The parties will also co-market their ScreenTape® and Seeplex® products in the global multiplex PCR diagnostics market.
Richard Rowling, Lab901’s Director of Sales & Marketing said “Lab901 is delighted to have secured this deal with Seegene. Combining Seegene’s highly multiplexed PCR diagnostic kits with Lab901’s simple and convenient automated analysis instrument will bring a great boost to both companies’ global sales”
Joel Fearnley, Co-founder and Chief Executive Officer of Lab901, commented “We are very excited about working with Seegene. The combination of their excellent multi-pathogen PCR tests with the simplicity, speed and sample traceability of the ScreenTape® system will be of real value to diagnostic microbiology and virology laboratories.”
“We are delighted to be working with Lab901 and we believe that their ScreenTape system will offer our global customer base a higher level of automation and standardisation.” commented Dr. Jong-Yoon Chun, Founder and Chief Executive Officer of Seegene.
Seegene’s Seeplex® tests are based on a breakthrough multiplexing PCR technology capable of detecting multiple pathogens in a single tube. Currently, Seeplex® tests offer laboratories worldwide, simple, cost-effective and comprehensive screening for Sexually Transmitted Diseases (STDs), respiratory viruses’, sepsis, human papillomavirus (HPV) and pneumonia.
Lab901 based in Edinburgh, UK, is a leading laboratory automation Company. The D800 ScreenTape® for DNA analysis was the first product from a pipeline of consumables that run on the company’s TapeStation™ instrument. The new DS12 ScreenTape® System, specifically developed for Seeplex® tests, automates the analysis of Seegene’s multi-pathogen PCR tests.
Contact: Richard Rowling +44 131 448 2904
About ScreenTape® System:
The ScreenTape® system is the first fully automated, walk-away solution for gel electrophoresis. Customers simply load their samples and the ScreenTape® into the compact TapeStation™ instrument. In just under 10 minutes, fully analysed results for DNA, RNA and protein samples are presented in an easy-to-interpret format.
Seegene, Inc. is pioneering the field of multi-pathogen testing. Seegene applies its novel and proprietary Seeplex® system utilizing “DPO (Dual Priming Oligo)” and “ACP (Annealing Control Primer)” to create multi-pathogen tests delivering maximum specificity, reproducibility and sensitivity. With over 260 citations and several patents and patents pending, Seegene has been offering advanced molecular diagnostics services to over 1,000 major global institutes in more than 25 countries. Seegene’s mission is to integrate Seeplex® with disease diagnostics to provide a new guideline for effectively treating patients. Seegene was founded in 2000 and is based in Rockville, MD and Seoul, Korea. For more information please visit
About the Seeplex® System: Frontier of Multi-pathogen Detection
Seeplex® is a breakthrough multiplexing PCR technology that enables a new standard in simultaneous multi-pathogen detection. Seeplex® works in combination with automatic detection systems such as ScreenTape® and delivers a benchmark in testing accuracy, efficiency and cost-effectiveness.